Related references
Note: Only part of the references are listed.Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis
Tomaz Kocjan et al.
ENDOCRINE PRACTICE (2021)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment
Nuria Guanabens et al.
ENDOCRINE (2019)
Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
Athanasios D. Anastasilakis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial
Rui Niimi et al.
JBMR PLUS (2018)
The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
Kosuke Ebina et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2017)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
JM Kaufman et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
R Lindsay et al.
ARCHIVES OF INTERNAL MEDICINE (2004)